Logo image of CERS

CERUS CORP (CERS) Stock Fundamental Analysis

NASDAQ:CERS - Nasdaq - US1570851014 - Common Stock - Currency: USD

1.515  -0.05 (-2.88%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CERS. CERS was compared to 187 industry peers in the Health Care Equipment & Supplies industry. CERS has a bad profitability rating. Also its financial health evaluation is rather negative. CERS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CERS had negative earnings in the past year.
CERS had a positive operating cash flow in the past year.
CERS had negative earnings in each of the past 5 years.
CERS had negative operating cash flow in 4 of the past 5 years.
CERS Yearly Net Income VS EBIT VS OCF VS FCFCERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

CERS's Return On Assets of -9.16% is fine compared to the rest of the industry. CERS outperforms 62.03% of its industry peers.
CERS's Return On Equity of -34.14% is in line compared to the rest of the industry. CERS outperforms 52.94% of its industry peers.
Industry RankSector Rank
ROA -9.16%
ROE -34.14%
ROIC N/A
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
CERS Yearly ROA, ROE, ROICCERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

CERS has a Gross Margin of 60.60%. This is comparable to the rest of the industry: CERS outperforms 59.89% of its industry peers.
In the last couple of years the Gross Margin of CERS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CERS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
CERS Yearly Profit, Operating, Gross MarginsCERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CERS has more shares outstanding
The number of shares outstanding for CERS has been increased compared to 5 years ago.
CERS has a worse debt/assets ratio than last year.
CERS Yearly Shares OutstandingCERS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CERS Yearly Total Debt VS Total AssetsCERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.74, we must say that CERS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.74, CERS is doing worse than 71.12% of the companies in the same industry.
The Debt to FCF ratio of CERS is 12.67, which is on the high side as it means it would take CERS, 12.67 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 12.67, CERS is in the better half of the industry, outperforming 74.33% of the companies in the same industry.
CERS has a Debt/Equity ratio of 1.17. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.17, CERS is not doing good in the industry: 80.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.17
Debt/FCF 12.67
Altman-Z -4.74
ROIC/WACCN/A
WACC9.37%
CERS Yearly LT Debt VS Equity VS FCFCERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

CERS has a Current Ratio of 2.32. This indicates that CERS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CERS (2.32) is comparable to the rest of the industry.
CERS has a Quick Ratio of 1.63. This is a normal value and indicates that CERS is financially healthy and should not expect problems in meeting its short term obligations.
CERS has a Quick ratio of 1.63. This is comparable to the rest of the industry: CERS outperforms 45.45% of its industry peers.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 1.63
CERS Yearly Current Assets VS Current LiabilitesCERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

CERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.33%, which is quite impressive.
CERS shows a small growth in Revenue. In the last year, the Revenue has grown by 7.86%.
CERS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.50% yearly.
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)7.86%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%12.7%

3.2 Future

The Earnings Per Share is expected to grow by 5.24% on average over the next years.
Based on estimates for the next years, CERS will show a quite strong growth in Revenue. The Revenue will grow by 9.19% on average per year.
EPS Next Y2.64%
EPS Next 2Y23.95%
EPS Next 3Y5.24%
EPS Next 5YN/A
Revenue Next Year24.23%
Revenue Next 2Y16.09%
Revenue Next 3Y9.19%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CERS Yearly Revenue VS EstimatesCERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M
CERS Yearly EPS VS EstimatesCERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CERS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CERS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERS Price Earnings VS Forward Price EarningsCERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

CERS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CERS is cheaper than 77.01% of the companies in the same industry.
Industry RankSector Rank
P/FCF 43.19
EV/EBITDA N/A
CERS Per share dataCERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.95%
EPS Next 3Y5.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CERS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERUS CORP

NASDAQ:CERS (7/3/2025, 11:22:19 AM)

1.515

-0.05 (-2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners74.53%
Inst Owner Change2.47%
Ins Owners3.15%
Ins Owner Change20.57%
Market Cap289.61M
Analysts80
Price Target4.76 (214.19%)
Short Float %3.68%
Short Ratio5.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.31%
Min EPS beat(2)6.63%
Max EPS beat(2)15.99%
EPS beat(4)4
Avg EPS beat(4)20.93%
Min EPS beat(4)6.63%
Max EPS beat(4)34.64%
EPS beat(8)6
Avg EPS beat(8)22.1%
EPS beat(12)8
Avg EPS beat(12)11.2%
EPS beat(16)12
Avg EPS beat(16)14.16%
Revenue beat(2)1
Avg Revenue beat(2)-7.11%
Min Revenue beat(2)-14.57%
Max Revenue beat(2)0.34%
Revenue beat(4)1
Avg Revenue beat(4)-5.41%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)0.34%
Revenue beat(8)1
Avg Revenue beat(8)-7.22%
Revenue beat(12)4
Avg Revenue beat(12)-4.31%
Revenue beat(16)8
Avg Revenue beat(16)0%
PT rev (1m)7.69%
PT rev (3m)19.66%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25%
EPS NY rev (1m)19.23%
EPS NY rev (3m)-34.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.67%
Revenue NY rev (1m)2.11%
Revenue NY rev (3m)-0.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.4
P/FCF 43.19
P/OCF 33.85
P/B 5.22
P/tB 5.35
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)0.04
FCFY2.32%
OCF(TTM)0.04
OCFY2.95%
SpS1.08
BVpS0.29
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.16%
ROE -34.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.6%
FCFM 3.24%
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
F-Score4
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity 1.17
Debt/FCF 12.67
Debt/EBITDA N/A
Cap/Depr 120.84%
Cap/Sales 0.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.32
Quick Ratio 1.63
Altman-Z -4.74
F-Score4
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)132.31%
Cap/Depr(5y)95.58%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y2.64%
EPS Next 2Y23.95%
EPS Next 3Y5.24%
EPS Next 5YN/A
Revenue 1Y (TTM)7.86%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%12.7%
Revenue Next Year24.23%
Revenue Next 2Y16.09%
Revenue Next 3Y9.19%
Revenue Next 5YN/A
EBIT growth 1Y39.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year170.67%
EBIT Next 3Y60.42%
EBIT Next 5YN/A
FCF growth 1Y141.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y167.58%
OCF growth 3YN/A
OCF growth 5YN/A